Creation of the Blind Amino Acid Riders (BAAR) involves an extremely complicated and timely 32-step Proprietary process developed by Dr. Ann de Wees Allen®, therefore the process for the production of BAAR is not published*.

Once the BAAR (minuscule glycoside slurry) has been produced in the laboratory, they are attached to the L-Arginine molecules that have been fermented, isolated, and cooled.

L-Arginine cannot cross the Blood Brain Barrier (BBB) without a Blind Amino Acid Rider, thus formulas that do not contain a BAAR do not successfully cross the BBB, and do not elicit a Growth Hormone/Anti-Aging response in humans.

The Blind Amino Acid Rider allows transport of the L-arginine molecules across the Blood-Brain-Barrier (BBB) in humans.

This requires that the Blind Amino Acid Rider is manufactured at the Nanoscale and Picoscale.

In its neuroprotective role, the Blood-Brain-Barrier (BBB) blocks agents from entering the brain.

Allowing therapeutic agents to cross the BBB without allowing dangerous agents access to the delicate brain-balance is a very intricate process involving many years of specialized research.

In a Tertiary Attachment Process, the L-arginine molecules (as processed herein) are biochemically attached to the BAAR (minimizing heat contact).

This allows the L-Arginine-BAAR to access the Blood-Brain-Barrier, as a “brain-friendly” agent, during Delta Sleep Cycle.

GH is a banned substance under International Doping Control Regulations, while naturally produced pituitary-GH is completely legal. The only legal form of GH in athletes is that which is produced by the pituitary gland in response to ingesting large amounts of the amino acid L-Arginine. This pulsatile form of GH is completely natural and does not possess any of the negative side effects related to synthetic GH.

The key factor in the natural generation of GH is to provide L-Arginine with a Blind Amino Acid Rider, which allows Arginine to cross the Blood-Brain Barrier.

The biochemical complexities of generating GH and testosterone in humans are based on the GH Production System (GHPS) in the pituitary gland. L-Arginine cannot cross the Blood-Brain Barrier (BBB) without a Blind Amino Acid Rider, as L-Arginine was identified as a Blind Amino Acid in 1983, and therefore incapable of crossing the BBB to elicit a GH response without a Rider.

The Johansson et al. clinical trials (1995) proved that GH could cross the BBB. In a cross-over, placebo-controlled, 9-month treatment study, Burman et al. (1996) confirmed the previous findings that GH can cross the Blood-Brain Barrier (BBB). If L-Arginine does not cross the BBB via a Blind Amino Acid Rider, no GH is produced.

The International Federation of Sports Medicine and the International Olympic Committee and Medical Commission state that “GH can allow an athlete to undergo harder training without negative changes by normalizing levels of monoamine metabolites and neuropeptides.” They also concluded that “GH can prevent psychological disruptions which could lead to negative impacts on concentration and motivation.”

Lack of motivation in athletes is a well recognized objective to success, and elevation or reinstation of GH levels results in significant increase in positive athletic output and attitude. Athletes that experience lack of confidence and slumps in performance typically suffer from low GH levels.

Neither Lysine, Ornithine, or Citrulline may be used in an L-Arginine formula capable of crossing the BBB to elicit a GH/Testosterone response. Though these ingredients are typically seen in L-Arginine formulas, they represent lack of knowledge in the field of L-Arginine biochemistry.

Once appropriate GH and testosterone levels are reached, the athlete can compete at world-class levels. This is of particular importance in athletes over age 25, as GH levels begin their decline at age 23, and accelerate as aging progresses. This decline causes dramatic reductions in sports performance, lean muscle mass, and increased body fat.

L-Arginine doses below 10,000 mg are completely ineffectual in generating Growth Hormone (GH). The system complexity of designing L-Arginine formulas that actually cross the BBB requires intricate knowledge of L-Arginine biochemistry and Blind Amino Acid Riders, as well as specific dose-timing properties of L-Arginine.

Without sufficient testosterone and GH, an athlete is doomed to failure.

In response to physiological stimulation, for example in endothelial cells and neurones, NO is generated rapidly and transiently at low (picomolar)(Pico-Size) concentrations.

NO’s solubility and diffusion properties closely resemble those of oxygen, and like oxygen, it is a gas under atmospheric conditions but a solute in biological systems.

In the immune system, Nitric Oxide evolved as a toxic molecule in innate defense, but in humans, its actions evolved to include immune regulation.

Avoiding the potential toxic qualities of Nitric Oxide (NO) requires utilization of Blind Amino Acid Riders, which negate the toxic properties of NO.

The BAAR Nanoparticles possess a diameter small enough to penetrate through diminutive capillaries into the cell's internal machinery to create a pre-programmed response.

BAAR facilitates access through endothelial-cell-gaps.

These gaps allow soluble BAAR to pass into the blood stream, where it is carried throughout the body, and subsequently passed out of the blood into different tissues.

In the brain, these endothelial cells are packed more tightly together, due to the existence of zonulae occludentes (tight junctions) between them, blocking the passage of most molecules.

The BAAR acts as a Carrier-Mediated-Transporter (CMT) for the amino acid L-arginine, with specific function in Nanoparticle biostrategy designed to allow transport across the Blood-Brain-Barrier.

It is currently impossible to “copy” or duplicate the BAAR Nanotechnology due to the minuscule size and complexity of the process and components used in the development process.

Thus, L-ARGININE BAAR and ArgMatrix® cannot be reverse engineered or copied.

Due to the high oxygen requirements, the L-Arginine-BAAR undergoes advanced purification.

Advanced purification methods are necessary to obtain pure Pharmaceutical Grade L-Arginine from fermentation.

The concentrated solution is cooled to ~ 10 degrees C to obtain amino acid crystals. The crystals are dried with a dryer to minimize moisture. The obtained amino acid crystals are 98.5 % pure Pharmaceutical Grade L-Arginine (PGLA). The PGLA crystals are then assayed and Elemental L-arginine levels are quantified.

Copyright® 2000-2011

THIS DOCUMENT MAY NOT BE COPIED

UNDER FEDERAL TRADEMARK & COPYRIGHT LAWS